Official Title
Prospective Observational Study for Patients With HIV and Confirmed SARS-CoV-2
Brief Summary

Currently, limited data is available about patients with HIV in the context of the COVID-19 pandemic. People with HIV who have not achieved viral suppression through antiretroviral treatment may have a compromised immune system that leaves them vulnerable to infections and disease progression. However, little is known about the presentation and clinical outcomes of patients with HIV and SARS-CoV-2. Our aim is to characterize the clinical presentation and disease course of COVID-19 in patients with HIV.

Detailed Description

Currently, limited data is available about patients with HIV in the context of the COVID-19
pandemic. People with HIV (PWH)/AIDS, or people with HIV who have not achieved viral
suppression through antiretroviral treatment may have at higher risk for SARS-CoV-2
infections and disease progression. At present there is no evidence to suggest that there is
an increased risk of infection and increased severity of illness for PWH. We know that during
the SARS and MERS outbreaks, there were only few case reports of mild disease among PWH.
Current clinical data suggest the main mortality risk factors are linked to older age and
other co-morbidities. However, some healthy people have also developed severe disease from
the SARS-CoV-2 infection.

This is a multi-center prospective observational study. Our aim is to characterize the
clinical presentation and clinical course of COVID-19 in patients with HIV.

Patients with HIV and confirmed SARS-Cov-2 will be identified during routine clinical care in
the inpatient or outpatient setting.

Contributors will share de-identified demographic data, health history data, and clinical
data pertaining the patient's presentation with COVID-19 and outcomes obtained during routine
care for their patients, using the secure online data collection tool REDCap.

Completed
HIV/AIDS
COVID-19
SARS-CoV-2

Other: No intervention

No intervention, observational study

Eligibility Criteria

Inclusion Criteria:

- HIV disease

- Laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain reaction
(PCR) or other commercial or public health assay

Exclusion Criteria:

- None

Eligibility Gender
All
Eligibility Age
Minimum: N/A ~ Maximum: N/A
Countries
United States
Locations

University of Missouri-Columbia
Columbia, Missouri, United States

University of Missouri-Columbia
NCT Number
Keywords
HIV
AIDS
Covid-19
SARS-CoV-2
clinical presentation
progression
clinical outcome
MeSH Terms
COVID-19